For sponsors and CROs, clinical trials for systemic lupus erythematosus (SLE or, more commonly, lupus) present a specific set of challenges that can impact the recruitment of investigators and patients and inhibit the ability to collect accurate data.


As a result, Clinical Ink developed a technology platform called the electronic Lupus Disease Assessment Suite (eLAS™) to improve and streamline the way data is collected for this specific therapeutic area. The launch of eLAS helped study teams drive protocol compliance and capture source data at the time of the patient visit, which improved data quality and integrity. 


This white paper discusses the challenges of diagnosing lupus, the unique difficulties lupus clinical trials face, and how the innovative eLAS platform helps meet these challenges.